Yahoo Finance Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Coherus BioSciences (NASDAQ:CHRS) First Quarter 2024 Results
Key Financial Results
Revenue: US$77.1m (up 138% from 1Q 2023).
Net income: US$102.9m (up from US$75.7m loss in 1Q 2023).
EPS: US$0.91 (up from US$0.95 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Coherus BioSciences EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 8.0%. Earnings per share (EPS) exceeded analyst estimates significantly.
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 16% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Coherus BioSciences (1 is potentially serious) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
